{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"183.67","value":"274.01"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"85.70","value":"380.28"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"title":"Cycle 1 Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"204.11","value":"522.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"161"}],"units":"Participants"}],"title":"Cycle 2 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"172"}],"units":"Participants"}],"description":"Ceoi is the plasma concentration observed at the end of intravenous infusion.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received isatuximab 10 mg/kg, IV infusion on Days 1, 8, 15 and 22 in Cycle 1, and then on Days 1 and Day 15 of each 28-day treatment cycle plus carfilzomib 20 mg/m\\^2, IV on Days 1, and 2 in Cycle 1, and then escalated to 56 mg/m\\^2 on Days 8, 9, 15 and 16 of Cycle 1 and then on Days 1, 2, 8, 9, 15 and 16 of each subsequent 28-day treatment cycle and dexamethasone 20 mg, PO or IV on Day 1, 2, 8, 9, 15, 16, 22 and 23 of each 28-day treatment cycle until disease progression or unacceptable adverse event or participant's decision to discontinue the study treatment or any other reason, whichever comes first (maximum exposure: 111 weeks).","id":"OG000","title":"Isatuximab + Carfilzomib + Dexamethasone (IKd)"}],"paramType":"MEAN","populationDescription":"Analysis was performed on pharmacokinetic (PK) population which included participants who received at least 1 dose of Isatuximab, with data for at least 1 PK parameter available. Data for this outcome measure (OM) was not planned to be collected and analyzed for Kd arm. Here, 'Number analyzed' signifies participants with available data for each specified category.","reportingStatus":"POSTED","timeFrame":"End of infusion on Cycle 1 Day 1 and Cycle 1 Day 15; Cycle 2 Day 1","title":"Pharmacokinetics: Plasma Concentration at End of Infusion (Ceoi) of Isatuximab: Primary Analysis","type":"SECONDARY","unitOfMeasure":"microgram/milliliter (mcg/mL)"}